ENCODE 计划揭示了人类基因组超过 80% 的基因组区域能够转录产生"暗物质"之称的 RNA。根据 RNA 的 5' 端是否具有帽子修饰结构，这些可以被分为两大 类：1）帽子结构的 （capped RNA，capRNA） ；2）非帽 RNA （noncapped RNA，napRNA） 。除 mRNA 和部分长非编码外，其余几乎所有均属于 napRNA。 这些 napRNA 不仅通过作为非编码 RNA （ncRNA） 调控多种生物学过程，还作为加工产物解析特定的 RNA 生物生成过程。然而，由于其长度异质性、末端修 饰多样性以及复杂的二级结构等，鉴定这些 napRNA 面临巨大挑战。 为应对这一挑战，中山大学生命科学学院 杨建华 / 李斌 / 屈良鹄 教授团队开发了 NAP-seq 技术，并于 2025 年 9 月 17 日在 Nature Protocols 期刊发表了题 为： NAP-seq for full-length noncapped RNA sequencing 的论文，系统介绍了该方法的设计原理与实验步骤。 编辑丨王多鱼 排版丨水成文 图1. NAP-seq的设计原理和实验步骤 NAP-s ...

内地和香港股市今年表现亮眼，陈东认为，这次中资股升浪与宏观基本面关系不大，目前中国宏观经济 增长仍乏力，通胀依然低企，尚未见到企业盈利预测上调，支持股市上升的动力主要来自中央去年九月 的政策支持承诺，市场预测每当经济增速减慢，便会有更多刺激措施推出。 他续称，中美紧张关系有降温迹象，双方均希望达成贸易协议，市场相信不会重返100%关税，预期中 美两国未来数月会有正式协议，变相降低中资股的风险溢价，加上人民银行为股市提供流动性支持措 施，AI主题亦带动科技股上扬，多个因素带动中资股获得估值重估，令外资对中国资产的兴趣提高， 当中较为熟悉中国的投资者最愿意重返中国市场，欧美投资者目前参与度仍偏低，但假若中资股升浪持 续，未来料有更多投资者回归。 美国不断收紧对华出口高科技产品的限制，瑞士百达财富管理亚洲首席策略师兼研究主管陈东指， DeepSeek令大家意识到中国在科技创新方面，与美国的差距并非很大，相信随着中国大力发展科技自 给自足战略，华为、阿里巴巴(09988)、百度(09888)等均自研芯片，未来将会出现两个科技生态系统， 中美或会迫使其他国家选择靠边站。 陈东指，中国股市正处于结构性改革阶段，科技股在中 ...

Core Insights - The 2025 China Small and Medium Cities High-Quality Development Index was released, highlighting the achievements of Yishui County in various national rankings [1] - Yishui County has improved its overall strength ranking, moving up 2 places to 85th, and has received three national honors in green development, investment potential, and new urbanization quality [1] Group 1: Industrial Development - Yishui County emphasizes industrial economy as a cornerstone for high-quality development, focusing on biomanufacturing and fine chemicals as key industries [1] - The county has established a "command + chain leader + special team" mechanism to enhance industrial growth, with a total industrial output value of 59.07 billion yuan, reflecting a year-on-year growth of 5.8% [2] Group 2: Urban-Rural Integration - Towns are seen as a bridge for urban-rural integration, with successful examples like Xujiahukou Town leveraging local resources for cultural and economic development [2] - Xujiahukou Town ranked 495th among the national top 1,000 towns, while Yangzhuang Town made its debut on the list at 983rd, showcasing the effectiveness of rural revitalization efforts [2] Group 3: Infrastructure and Public Services - Infrastructure improvements are underway, including transportation and public service upgrades, enhancing the quality of life for residents [3] - Initiatives such as old community renovations and public service enhancements are contributing to a better living environment and community well-being [3] Group 4: Social Development - The county's social development is marked by strong governance and community engagement, with events like the 2025 Shandong (Yishui) Food Expo attracting nearly 400 quality enterprises [3] - Cultural initiatives and community programs are fostering a vibrant social atmosphere, promoting reading and cultural activities [3] Group 5: Future Prospects - Yishui County's comprehensive development strategy positions it favorably in the competitive landscape of county-level governance, contributing to the revitalization of the Yimeng revolutionary area [4] - The county aims to continue enhancing its industrial base, urban-rural integration, and social welfare to achieve sustainable growth [4]

Group 1 - Jiangxi Chunyu Biotechnology Co., Ltd. has been established with a registered capital of 2 million RMB [1] - The legal representative of the company is Zhang Jianjun [1] - The business scope includes licensed projects such as beauty services and various retail and wholesale activities related to cosmetics and daily necessities [1] Group 2 - The company is involved in the promotion of new material technology and sales of non-food plant oils, disinfectants, and daily chemical products [1] - It also engages in domestic trade agency and import-export activities, excluding projects that require approval [1]

Core Viewpoint - The Hong Kong stock market experienced a collective decline in key indices, influenced by hawkish signals from the Federal Reserve, with the Hang Seng Biotechnology Index dropping over 2% at one point [1] Group 1: Market Performance - The largest ETF tracking the Hang Seng Biotechnology Index, the Hang Seng Medicine ETF (159892), saw active trading, with a transaction value exceeding 500 million as of 10:48 AM, ranking first among its peers [1] Group 2: Policy Developments - The 11th batch of centralized drug procurement is progressing steadily, with the National Medical Insurance Administration releasing procurement documents on September 20. The new procurement strategy will not simply use the lowest bid as a benchmark; instead, if the lowest price is below 50% of the average winning price, the latter will serve as the price control anchor [1] - This approach aims to prevent vicious low-price competition among companies, protect reasonable profits, and ensure better drug quality [1] Group 3: Industry Insights - According to Huaxin Securities, under the current domestic innovative payment system, some innovative products have achieved a positive cycle of R&D investment returns, with sales reaching new highs. Additionally, overseas clinical data is being released, and the peak of external licensing is approaching, accelerating the realization of innovative value [1]

Group 1 - The total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% rise, indicating a major shift in market recognition of local pharmaceutical companies' innovation capabilities [1] - The expectation of the Federal Reserve accelerating interest rate cuts is anticipated to boost risk appetite, directing funds towards growth sectors such as Chinese biotech [1] - Individual stock performance will still depend on company fundamentals, including commercialization execution and innovation research progress [1] Group 2 - Companies with short-term catalysts that are favored include Kangfang Biotech (09926), Innovent Biologics (09969), Huyou-B (02256), Sinopharm (01801), and Eucure Biopharma-B (09606) [1] - Morgan Stanley has given "outperform" ratings to Weisheng Pharmaceutical-B (02561) and Zai Lab (09688) [1]

Core Viewpoint - Faraday Future (FFAI.US) stock price declined over 8% to $1.625 following the announcement of a $41 million investment in Qualigen Therapeutics (QLGN.US) to support its entry into the crypto and Web3 sectors [1] Group 1: Company Actions - Faraday Future announced a $41 million investment in Qualigen Therapeutics to facilitate its expansion into the crypto and Web3 markets [1] - This investment will provide Faraday Future with significant equity in Qualigen and plans to appoint a management team to lead new business activities [1] Group 2: Market Reactions - Following the investment announcement, Qualigen Therapeutics' stock surged over 95%, reaching $5.55 [1]

禾元生物成为科创成长层新注册企业中首家启动发行工作的企业。 9月22日晚，武汉禾元生物科技股份有限公司（简称"禾元生物"）在上交所网站披露招股意向书、发行 安排及初步询价公告，正式启动发行工作。这意味着，禾元生物将成为科创成长层新注册企业中首家启 动发行工作的企业。 禾元生物启动发行，是落实科创板"1+6"改革、增强对优质科技型企业的制度包容性和适应性的重要体 现，彰显了尊重科技创新规律、支持优质科技企业发展、更好服务新质生产力的政策导向。 值得一提的是，根据"科创板八条"的相关试点安排，禾元生物也是首家采用网下发行差异化限售与配售 安排的公司。根据禾元生物披露的公告文件，其网下整体限售比例不低于40%，对投资者报价设置了3 档差异化限售档位，申购最高限售档位投资者的配售比例不低于最低限售档位的9倍。 市场人士指出，今年3月上交所修订发行承销业务规则，明确未盈利企业可以采用约定限售方式，网下 投资者自愿报价申购，履行限售更高比例、更长期限的承诺和义务并相应获配较多的新股，鼓励更 多"看得准、拿得住"的专业机构在新股发行定价中发挥更大作用，促进新股合理定价。 今年以来，上交所持续推进"科创板八条"和科创板"1+ ...

自今年6月科创板"1+6"改革政策以来，科创板新增受理15家公司IPO申请，其中4家为未盈利企业，1家 适用第五套标准。目前，已有3家未盈利企业IPO注册生效，其中2家为第五套标准企业。禾元生物也是 重启科创板第五套标准后的首家过会并取得注册批文的企业。 证券时报记者获悉，目前，科创成长层首批新注册企业发行上市的各项工作正在有序稳步推进中，上交 所技术系统完成全网通关测试，已于近日陆续上线。证券公司已有序组织投资者签署参与科创成长层交 易的风险揭示书，目前已有500万户投资者开通科创成长层交易权限。 禾元生物启动发行，是落实科创板"1+6"改革、增强对优质科技型企业的制度包容性和适应性的重要体 现，彰显了尊重科技创新规律、支持优质科技企业发展、更好服务新质生产力的政策导向。 值得一提的是，根据"科创板八条"的相关试点安排，禾元生物也是首家采用网下发行差异化限售与配售 安排的公司。根据禾元生物披露的公告文件，其网下整体限售比例不低于40%，对投资者报价设置了3 档差异化限售档位，申购最高限售档位投资者的配售比例不低于最低限售档位的9倍。 禾元生物成为科创成长层新注册企业中首家启动发行工作的企业。 9月22日晚， ...

禾元生物成为科创成长层新注册企业中首家启动发行工作的企业。 9月22日晚，武汉禾元生物科技股份有限公司（简称"禾元生物"）在上交所网站披露招股意向书、发行安 排及初步询价公告，正式启动发行工作。这意味着，禾元生物将成为科创成长层新注册企业中首家启动发 行工作的企业。 | 688765 | 禾元生物 | 禾元生物首次公开发行股票并在科创板上市招股意向书附录 | 2025-09-23 | | --- | --- | --- | --- | | 688765 | 禾元生物 | 禾元生物首次公开发行股票并在科创板上市招股意向书提示性公告 | 2025-09-23 | | 688765 | 禾元生物 | 天元生物首次公开发行股票并在科创板上市发行安排及初步询价公告 | 2025-09-23 | | 688765 | 禾元生物 | 不元生物首次公开发行股票并在科创板上市招股意向书 | 2025-09-23 | 根据禾元生物发行安排，该公司拟于10月13日刊登发行公告，10月14日正式发行。 | 本次发行重要日期 | | | | | --- | --- | --- | --- | | 初步询价日及起止 | 2025年10月 ...